154 related articles for article (PubMed ID: 18460561)
1. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
Fusco A; Zatelli MC; Bianchi A; Cimino V; Tilaro L; Veltri F; Angelini F; Lauriola L; Vellone V; Doglietto F; Ambrosio MR; Maira G; Giustina A; degli Uberti EC; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2008 Jul; 93(7):2746-50. PubMed ID: 18460561
[TBL] [Abstract][Full Text] [Related]
2. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
3. The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas.
Selek A; Cetinarslan B; Canturk Z; Tarkun I; Hanazay Y; Vural C; Anik I; Ceylan S
Growth Horm IGF Res; 2019 Apr; 45():1-5. PubMed ID: 30731342
[TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
[TBL] [Abstract][Full Text] [Related]
5. Cavernous sinus invasion and effect of immunohistochemical features on remission in growth hormone secreting pituitary adenomas.
Yilmaz M; Vural E; Koc K; Ceylan S
Turk Neurosurg; 2015; 25(3):380-8. PubMed ID: 26037177
[TBL] [Abstract][Full Text] [Related]
6. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas.
Losa M; Ciccarelli E; Mortini P; Barzaghi R; Gaia D; Faccani G; Papotti M; Mangili F; Terreni MR; Camanni F; Giovanelli M
J Clin Endocrinol Metab; 2001 Nov; 86(11):5194-200. PubMed ID: 11701676
[TBL] [Abstract][Full Text] [Related]
7. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
8. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
9. Role of Ki-67 in acromegalic patients with hyperprolactinemia: retrospective analysis in 61 Chinese Patients.
Huan C; Cui G; Lu C; Qu X; Han T
Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):719-23. PubMed ID: 25796164
[TBL] [Abstract][Full Text] [Related]
10. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
Shimon I; Jallad RS; Fleseriu M; Yedinak CG; Greenman Y; Bronstein MD
Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
[TBL] [Abstract][Full Text] [Related]
11. Expression of voltage gated potassium channel ether à go-go in pituitary adenomas of patients with acromegaly: A preliminary study.
Zuhur SS; Ozkayalar H; Kuzu I; Ozturk FY; Elbuken G; Tanik C; Altuntas Y
Neuro Endocrinol Lett; 2015; 36(2):165-70. PubMed ID: 26071586
[TBL] [Abstract][Full Text] [Related]
12. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
14. [Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].
Brito J; Sáez L; Lemp M; Liberman C; Michelsen H; Araya AV
Rev Med Chil; 2008 Jul; 136(7):831-6. PubMed ID: 18949157
[TBL] [Abstract][Full Text] [Related]
15. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
18. Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience.
Lv L; Hu Y; Zhou P; Zhang S; Yin S; Zhang N; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():24-30. PubMed ID: 29433055
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acromegaly in the era of personalized and predictive medicine.
Puig Domingo M
Clin Endocrinol (Oxf); 2015 Jul; 83(1):3-14. PubMed ID: 25640882
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report.
Waligórska-Stachura J; Gut P; Sawicka-Gutaj N; Liebert W; Gryczyńska M; Baszko-Błaszyk D; Blanco-Gangoo AR; Ruchała M
J Neurosurg; 2016 Aug; 125(2):346-9. PubMed ID: 26636388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
